
Keywords: MN; micronucleus; CA; chromosomal aberrations; CBMN; cytokinesis-block micronucleus assay; GSH; glutathione; IARC; International Agency for Research on Cancer; i.p.; intraperitonelly; LOEL; lowest observed effect level; MTD; maximum tolerated dose; NOEL;